[go: up one dir, main page]

MXPA02003122A - Acidos indolalcanoicos substituidos. - Google Patents

Acidos indolalcanoicos substituidos.

Info

Publication number
MXPA02003122A
MXPA02003122A MXPA02003122A MXPA02003122A MXPA02003122A MX PA02003122 A MXPA02003122 A MX PA02003122A MX PA02003122 A MXPA02003122 A MX PA02003122A MX PA02003122 A MXPA02003122 A MX PA02003122A MX PA02003122 A MXPA02003122 A MX PA02003122A
Authority
MX
Mexico
Prior art keywords
indolealkanoic acids
substituted
substituted indolealkanoic
compounds
disclosed
Prior art date
Application number
MXPA02003122A
Other languages
English (en)
Inventor
David Gunn
Original Assignee
Inst For Pharm Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst For Pharm Discovery Inc filed Critical Inst For Pharm Discovery Inc
Publication of MXPA02003122A publication Critical patent/MXPA02003122A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Se describen acidos indolalcanoicos sustituidos utiles en el tratamiento de complicaciones cronicas que se originan de diabetes mellitus. Tambien se describen composiciones farmaceuticas que contienen los compuestos y metodos de tratamiento que emplean los compuestos, asi como metodos para su sintesis.
MXPA02003122A 1998-03-31 1999-03-31 Acidos indolalcanoicos substituidos. MXPA02003122A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8014398P 1998-03-31 1998-03-31
PCT/US1999/007116 WO1999050268A2 (en) 1998-03-31 1999-03-31 Substituted indolealkanoic acids

Publications (1)

Publication Number Publication Date
MXPA02003122A true MXPA02003122A (es) 2004-04-21

Family

ID=22155536

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02003122A MXPA02003122A (es) 1998-03-31 1999-03-31 Acidos indolalcanoicos substituidos.

Country Status (29)

Country Link
US (9) US6214991B1 (es)
EP (1) EP1066283B1 (es)
JP (2) JP3494990B2 (es)
KR (1) KR100584650B1 (es)
CN (1) CN1205207C (es)
AP (1) AP2000001929A0 (es)
AT (1) ATE269861T1 (es)
AU (1) AU774929B2 (es)
BG (1) BG65446B1 (es)
BR (1) BR9909358A (es)
CA (1) CA2383983C (es)
CZ (1) CZ300706B6 (es)
DE (1) DE69918278T2 (es)
EE (1) EE200000573A (es)
ES (1) ES2224632T3 (es)
HU (1) HUP0101672A3 (es)
ID (1) ID27884A (es)
IL (2) IL138711A0 (es)
MX (1) MXPA02003122A (es)
NO (1) NO20004900L (es)
NZ (1) NZ507172A (es)
OA (1) OA11622A (es)
PL (1) PL201645B1 (es)
SK (1) SK7522001A3 (es)
TR (1) TR200002869T2 (es)
TW (1) TWI243163B (es)
WO (1) WO1999050268A2 (es)
YU (1) YU59600A (es)
ZA (1) ZA200005577B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214991B1 (en) * 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
JP2003505369A (ja) * 1999-07-15 2003-02-12 エヌピーエス アレリックス コーポレーション 偏頭痛を治療するための複素環式化合物
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor
US20020012630A1 (en) * 2000-05-09 2002-01-31 James Nolan Methods for testing compounds useful in treating diabetic complications
WO2002051805A1 (de) 2000-12-27 2002-07-04 Bayer Aktiengesellschaft Indol-derivate
TWI224101B (en) 2001-06-20 2004-11-21 Wyeth Corp Substituted naphthyl indole derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1)
DK1397130T3 (da) 2001-06-20 2007-11-12 Wyeth Corp Substituerede indolsyrederivater som inhibitorer af plasminogenaktivatorinhibitor-1 (PAI-1)
AU2003210610B2 (en) 2002-01-18 2007-11-29 Aryx Therapeutics 5-HT3 receptor antagonists and methods of use
US20060100255A1 (en) * 2002-07-26 2006-05-11 Van Zandt Michael C Substituted indolealkanoic acids derivative and formulations containing same for use in the treatment of diabetic complications
CA2395871A1 (en) * 2002-07-26 2004-01-26 The Institutes For Pharmaceutical Discovery, Llc Substituted indolealkanoic acids derivatives and formulations containing same for use in treatment of diabetic complications
RU2328483C2 (ru) * 2002-08-29 2008-07-10 Мерк Энд Ко., Инк. Индолы, обладающие противодиабетической активностью
DE60324183D1 (en) 2002-12-10 2008-11-27 Wyeth Corp Aryl-, aryloxy- und alkyloxysubstituierte 1h-indol-3-yl-glyoxylsäurederivateals inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
UA80453C2 (en) 2002-12-10 2007-09-25 Derivatives of substituted dyhydropyranoindol-3,4-dion as inhibitors of plasminogen activator inhibitor-1 (pai-1)
JP2006514637A (ja) 2002-12-10 2006-05-11 ワイス プラスミノーゲン活性化因子の阻害因子−１（ｐａｉ−１）の阻害剤としての置換３−カルボニル−１ｈ−インドール−１−イル酢酸誘導体
ATE430731T1 (de) 2002-12-10 2009-05-15 Wyeth Corp Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
DK1569899T3 (da) 2002-12-10 2006-10-23 Wyeth Corp Substituerede 3-alkyl- og 3-arylalkyl-1H-indol-1-yl-eddikesyrederivater som inhibitorer af plasminogenaktivator-inhibitor-1 (PAI-1)
EP1620088A4 (en) * 2003-04-28 2007-08-29 Bayer Pharmaceuticals Corp ACETIC INDOLE ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICAL AGENTS
CN1812977A (zh) * 2003-04-30 2006-08-02 药物研发有限责任公司 取代羧酸
CA2534649A1 (en) * 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
US7265148B2 (en) 2003-09-25 2007-09-04 Wyeth Substituted pyrrole-indoles
US7351726B2 (en) 2003-09-25 2008-04-01 Wyeth Substituted oxadiazolidinediones
US7411083B2 (en) 2003-09-25 2008-08-12 Wyeth Substituted acetic acid derivatives
US7446201B2 (en) 2003-09-25 2008-11-04 Wyeth Substituted heteroaryl benzofuran acids
US7163954B2 (en) 2003-09-25 2007-01-16 Wyeth Substituted naphthyl benzothiophene acids
US7332521B2 (en) 2003-09-25 2008-02-19 Wyeth Substituted indoles
US7268159B2 (en) 2003-09-25 2007-09-11 Wyeth Substituted indoles
US7141592B2 (en) 2003-09-25 2006-11-28 Wyeth Substituted oxadiazolidinediones
US7442805B2 (en) 2003-09-25 2008-10-28 Wyeth Substituted sulfonamide-indoles
US7582773B2 (en) 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
JP2008518926A (ja) * 2004-10-28 2008-06-05 ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー 置換フェニルアルカン酸
JP2008526980A (ja) * 2005-01-14 2008-07-24 ジェネラブズ テクノロジーズ インコーポレーティッド ウイルス感染症を治療するためのインドール誘導体
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US20080051384A1 (en) * 2006-07-14 2008-02-28 Genelabs Technologies, Inc. Antiviral agents
EP2046740B1 (en) 2006-07-22 2012-05-23 Oxagen Limited Compounds having crth2 antagonist activity
ES2442717T3 (es) 2008-01-18 2014-02-13 Atopix Therapeutics Limited Compuestos que tienen actividad antagonista de CRTH2
US7750027B2 (en) * 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2009093029A1 (en) * 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
WO2009093026A1 (en) 2008-01-22 2009-07-30 Oxagen Limited Compounds having crth2 antagonist activity
GB2457040A (en) * 2008-01-30 2009-08-05 Oxagen Ltd 1-Acetic acid indole derivatives with PGD2 activity
WO2010127099A2 (en) 2009-04-29 2010-11-04 Amarin Corporation Plc Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same
PL3597650T3 (pl) * 2010-07-16 2023-02-06 The Trustees Of Columbia University In The City Of New York Inhibitory reduktazy aldozy i ich zastosowania
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
GB201322273D0 (en) 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
DK3757107T3 (da) 2016-06-21 2023-11-27 Univ Columbia 4-oxo-3,4-dihydrothieno[3,4-d]pyridazinforbindelser som aldosereduktasehæmmere og metoder til anvendelse deraf
PT3658142T (pt) 2017-07-28 2024-06-27 Applied Therapeutics Inc Composições e métodos para tratar galactosemia
WO2019191410A1 (en) * 2018-03-29 2019-10-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitors for the β-catenin / t-cell factor protein–protein interaction
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
CA3136100A1 (en) 2019-05-07 2020-11-12 Stephan L. ZUCHNER Treatment and detection of inherited neuropathies and associated disorders

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3557142A (en) 1968-02-20 1971-01-19 Sterling Drug Inc 4,5,6,7-tetrahydro-indole-lower-alkanoic acids and esters
IE47592B1 (en) 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
DK151884C (da) * 1979-03-07 1988-06-13 Pfizer Analogifremgangsmaade til fremstilling af 3-(1-imidazolylalkyl)indolderivater eller farmaceutisk acceptable syreadditionssalte deraf
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
US4283539A (en) 1979-12-18 1981-08-11 Pfizer Inc. Isoquinoline acetic acids
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
US4442118A (en) 1981-07-23 1984-04-10 Ayerst, Mckenna & Harrison, Inc. Aldose reductase inhibition by 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid
GB8607294D0 (en) 1985-04-17 1986-04-30 Ici America Inc Heterocyclic amide derivatives
EP0222576B1 (en) * 1985-11-07 1992-03-18 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4960785A (en) * 1988-12-16 1990-10-02 Pfizer Inc. Indolinone derivatives
WO1993012786A1 (en) * 1986-07-10 1993-07-08 Howard Harry R Jr Indolinone derivatives
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US5064852A (en) * 1988-12-16 1991-11-12 Pfizer Inc. Indolinone derivatives
KR920700210A (ko) 1989-03-31 1992-02-19 기따미 가즈히꼬 신규 이미다졸 유도체, 그의 제법 및 그의 의약용도
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
GB8916774D0 (en) * 1989-07-21 1989-09-06 Bayer Ag New indole derivatives,a process for their preparation and their use in medicaments
US5304557A (en) 1989-12-15 1994-04-19 Pfizer Inc. Substituted oxoophthalazinyl acetic acids and analogs thereof
GB9011335D0 (en) 1990-05-21 1990-07-11 Fujisawa Pharmaceutical Co Indolebutyric acid derivatives and process for preparation thereof
US5312829A (en) * 1990-05-21 1994-05-17 Fujisawa Pharmaceutical Co., Ltd. Indole derivatives
US5236945A (en) * 1990-06-11 1993-08-17 Pfizer Inc. 1H-indazole-3-acetic acids as aldose reductase inhibitors
US5116753A (en) 1991-07-30 1992-05-26 The Salk Institute For Biological Studies Maintenance of pancreatic islets
JPH0641071A (ja) * 1991-09-06 1994-02-15 Taisho Pharmaceut Co Ltd インドール酢酸エステル誘導体
GB9122590D0 (en) 1991-10-24 1991-12-04 Lilly Industries Ltd Pharmaceutical compounds
US5391551A (en) 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
GB9317764D0 (en) * 1993-08-26 1993-10-13 Pfizer Ltd Therapeutic compound
GB9409583D0 (en) 1994-05-13 1994-07-06 Pfizer Ltd Indoles
US5641800A (en) * 1994-07-21 1997-06-24 Eli Lilly And Company 1H-indole-1-functional sPLA2 inhibitors
TW401301B (en) 1994-10-07 2000-08-11 Takeda Chemical Industries Ltd Antihypertriglyceridemic composition
US5700819A (en) * 1994-11-29 1997-12-23 Grelan Pharmaceutical Co., Ltd. 2-substituted benzothiazole derivatives and prophylactic and therapeutic agents for the treatment of diabetic complications
IL117208A0 (en) * 1995-02-23 1996-06-18 Nissan Chemical Ind Ltd Indole type thiazolidines
WO1996029075A1 (en) * 1995-03-20 1996-09-26 Eli Lilly And Company 5-substituted-3-(1,2,3,6-tetrahydropyridin-4-yl)- and 3-(piperidin-4-yl)-1h-indoles: new 5-ht1f agonists
JPH09165371A (ja) 1995-10-09 1997-06-24 Sankyo Co Ltd 複素環化合物を含有する医薬
DE19636150A1 (de) * 1996-09-06 1998-03-12 Asta Medica Ag N-substituierte Indol-3-glyoxylamide mit antiasthmatischer, antiallergischer und immunsuppressiver/immunmodulierender Wirkung
US6214991B1 (en) 1998-03-31 2001-04-10 The Institute For Pharmaceutical Discovery, Inc. Substituted indolealkanoic acids
TNSN99224A1 (fr) * 1998-12-01 2005-11-10 Inst For Pharm Discovery Inc Methodes de reduction des niveaux de glucose et triglyceride en serum et pour suppression de l'antigenese utilisant les acides la indolealkanoique
WO2001064205A2 (en) * 2000-03-02 2001-09-07 The Institutes For Pharmaceutical Discovery, Llc Compositions containing a substituted indolealkanoic acid and an angiotensin converting enzyme inhibitor

Also Published As

Publication number Publication date
BG65446B1 (bg) 2008-08-29
NZ507172A (en) 2003-10-31
US20070093530A1 (en) 2007-04-26
AU774929B2 (en) 2004-07-15
US7105514B2 (en) 2006-09-12
US20100137301A1 (en) 2010-06-03
AU3459599A (en) 1999-10-18
US20080214540A1 (en) 2008-09-04
JP3494990B2 (ja) 2004-02-09
JP2002509931A (ja) 2002-04-02
BG104819A (en) 2001-05-31
US6730794B2 (en) 2004-05-04
CA2383983A1 (en) 1999-10-07
HUP0101672A3 (en) 2002-05-28
YU59600A (sh) 2002-12-10
EP1066283B1 (en) 2004-06-23
US20030018053A1 (en) 2003-01-23
US20010016661A1 (en) 2001-08-23
US20040235933A1 (en) 2004-11-25
US7304079B2 (en) 2007-12-04
EE200000573A (et) 2002-04-15
BR9909358A (pt) 2000-12-12
DE69918278D1 (de) 2004-07-29
SK7522001A3 (en) 2002-02-05
OA11622A (en) 2004-09-16
US20120270912A1 (en) 2012-10-25
US6214991B1 (en) 2001-04-10
PL201645B1 (pl) 2009-04-30
US7659269B2 (en) 2010-02-09
DE69918278T2 (de) 2005-07-14
ID27884A (id) 2001-05-03
WO1999050268A3 (en) 1999-12-16
IL138711A (en) 2006-09-05
KR100584650B1 (ko) 2006-05-30
PL348244A1 (en) 2002-05-20
CZ300706B6 (cs) 2009-07-22
TR200002869T2 (tr) 2000-12-21
US6426344B2 (en) 2002-07-30
EP1066283A2 (en) 2001-01-10
US20100324039A1 (en) 2010-12-23
ES2224632T3 (es) 2005-03-01
US8163932B2 (en) 2012-04-24
WO1999050268A2 (en) 1999-10-07
TWI243163B (en) 2005-11-11
ATE269861T1 (de) 2004-07-15
CZ20003607A3 (cs) 2001-03-14
CN1205207C (zh) 2005-06-08
CA2383983C (en) 2009-09-29
NO20004900D0 (no) 2000-09-29
NO20004900L (no) 2000-10-17
HUP0101672A2 (hu) 2002-04-29
KR20010042330A (ko) 2001-05-25
IL138711A0 (en) 2001-10-31
ZA200005577B (en) 2002-02-11
AP2000001929A0 (en) 2000-09-30
CN1296485A (zh) 2001-05-23
JP2003155274A (ja) 2003-05-27

Similar Documents

Publication Publication Date Title
AP2000001929A0 (en) Substituted indolealkanoic acids.
AU2002350191A8 (en) Substituted heteroarylalkanoic acids and their use as aldose reductase inhibitors
YU73600A (sh) Novi nukleosidi koji imaju biciklične šećerne grupe
BG103268A (en) Propionic acid derivatives and their application
AP2001002377A0 (en) Substituted phenoxyacetic acids.
AU2000276362A1 (en) Composition for the treatment of diabetes
WO2001010894A3 (en) Antipicornaviral compounds and compositions, their pharmaceutical uses, and materials for their synthesis
WO2000066528A3 (en) Quinones for treatment of diseases
MXPA03001463A (es) Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen.
MY134167A (en) Biphenylcarboxamides useful as lipid lowering agents
WO2002016340A8 (fr) Aminoalkoxybenzoyl-benzofuranes ou benzothiophenes, leur procede de preparation et les compositions les contenant
HUP9601321A2 (en) Substituted (benzyloxy)-carbonyl-guanidine derivatives, process for producing them, pharmaceutical compositions containing them their use as pharmaceutical compositions or diagnostica, and the use of the said compds.
WO2003020963A3 (en) Proteins in type 2 diabetes
AU4925200A (en) Oral composition containing perlite
YU46302A (sh) Supstituisani piroli
MY138338A (en) Substituted indolealkanoic acids
WO1999048851A3 (en) Processes for preparing intermediates
EP0386920A3 (en) 2-hydroxy-3-thienyloxypropylamino derivatives
BG107553A (en) Aminoalkenylbenzoyl-benzofuran or benzothiophene derivatives, methods for preparing same and compositions containing same
DE50006244D1 (en) Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine
AU3744100A (en) Bicyclo(3.3.1)nonenes useful for the treatment of diabetes
WO1999040078A3 (en) Process for the preparation of sotolon
MXPA05003633A (es) 2"-oxo-voruscharina y derivados de la misma.
PL346003A1 (en) N-substituted azabicycloheptane derivatives, production and use thereof
AU2003298203A1 (en) Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles

Legal Events

Date Code Title Description
FG Grant or registration